Organon vs Perrigo
OGN and PRGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OGN and PRGO compare
Organon is the larger company, worth 1.6 times as much as Perrigo ($3.7B against $2.3B).
Organon grew revenue faster over the last twelve months (−3.2% versus −4.5% for Perrigo).
Organon keeps more of each dollar of sales as profit, with a net margin of 3.5% compared with −43.3% at Perrigo.
Both pay dividends: Organon yields 0.58% and Perrigo 5.4%.
Perrigo scores higher on the StockData Score (10 against 8 for Organon), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OGN | PRGO |
|---|---|---|
| Size and price | ||
| Market cap | $3.7B | $2.3B |
| Share price | $13.90 | $16.24 |
| Change, 1 year | 80.3% | 14.7% |
| Change, 5 years | −55.5% | −60.5% |
| Beta (5Y) | 0.82 | 0.59 |
| Employees | 10K | 8,100 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 2 | 2 |
| Health score | 1 | 1 |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 18.1× | – |
| P/S | 0.6× | 0.6× (better) |
| P/B | 3.1× | 0.9× (better) |
| P/FCF | 5.4× (better) | 13.4× |
| FCF yield | 18.5% (better) | 7.5% |
| Fair value | $15.38 | $22.75 |
| Margin of safety | 9.6% | 28.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −3.2% (better) | −4.5% |
| Revenue growth, 5Y average | −0.99% | 0.79% (better) |
| Net income growth (TTM) | −57.5% | – |
| EPS growth (TTM) | −59.9% | – |
| EPS growth, 5Y average | −39.0% | – |
| Profitability | ||
| Gross margin | 53.1% (better) | 32.3% |
| Operating margin | – | −39.4% |
| Net margin | 3.5% (better) | −43.3% |
| FCF margin | 11.1% (better) | 4.1% |
| Return on equity | 20.3% (better) | −51.4% |
| Return on invested capital | – | −19.7% |
| Financial health | ||
| Debt / equity | 7.17 | 1.35 (better) |
| Current ratio | 2.02 | 2.35 (better) |
| Altman Z-score | 1.04 (better) | −0.43 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.58% | 5.4% (better) |
| Payout ratio | 9.4% | – |
| Years of dividend growth | 0 | 11 (better) |
| Dividend growth, 5Y average | – | 5.2% |
| Shareholder yield | 0.58% | 5.4% (better) |
| Ownership | ||
| Held by institutions | 83.3% | 116% |
| Held by insiders | 0.47% | 0.36% |
| Insider net buying, 12 months | −$200K | $0 (better) |
| Short interest, % of float | 7.5% | 17.8% |
Go deeper
- OGN stock overview
- OGN income statement
- OGN valuation and score
- PRGO stock overview
- PRGO income statement
- PRGO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.